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Articles
Sorafenib in combination with transarterial 
chemoembolisation in patients with unresectable 
hepatocellular carcinoma (TACE 2): a randomised 
placebo-controlled, double-blind, phase 3 trial
Tim Meyer, Richard Fox, Yuk Ting Ma, Paul J Ross, Martin W James, Richard Sturgess, Clive Stubbs, Deborah D Stocken, Lucy Wall, Anthony Watkinson, 
Nigel Hacking, T R Jeffry Evans, Peter Collins, Richard A Hubner, David Cunningham, John Neil Primrose, Philip J Johnson, Daniel H Palmer
Summary
Background Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage 
hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. 
We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.
Methods We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for 
patients with unresectable, liver-confined hepatocellular carcinoma. Patients were eligible if they were at least aged 
18 years, had Eastern Cooperative Oncology Group performance status of 1 or less, and had Child-Pugh A liver disease. 
Patients were randomised 1:1 by computerised minimisation algorithm to continuous oral sorafenib (400 mg twice-daily) 
or matching placebo combined with TACE using drug-eluting beads (DEB-TACE), which was given via the hepatic artery 
2–5 weeks after randomisation and according to radiological response and patient tolerance thereafter. Patients were 
stratified according to randomising centre and serum α-fetoprotein concentration (<400 ng/mL and ≥400 ng/mL). Only 
the trial coordinator was unmasked to treatment allocation before patient progression during the study. The primary 
endpoint was progression-free survival defined as the interval between randomisation and progression according to 
Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause, and was analysed by 
intention-to-treat. Safety was analysed by intention-to-treat. The trial has been completed and the final results are 
reported. The trial is registered at EudraCT, number 2008-005073-36, and ISRCTN, number ISRCTN93375053.
Findings Between Nov 4, 2010, and Dec 7, 2015, the trial enrolled 399 patients and was terminated after a planned 
interim futility analysis. 86 patients failed screening and 313 remaining patients were randomly assigned: 157 to 
sorafenib and 156 to placebo. The median daily dose was 660 mg (IQR 389·2–800·0) sorafenib versus 800 mg 
(758·2–800·0) placebo, and median duration of therapy was 120·0 days (IQR 43·0–266·0) for sorafenib versus 
162·0 days (70·0–323·5) for placebo. There was no evidence of difference in progression-free survival between the 
sorafenib group and the placebo group (hazard ratio [HR] 0·99 [95% CI 0·77–1·27], p=0·94); median progression-free 
survival was 238·0 days (95% CI 221·0–281·0) in the sorafenib group and 235·0 days (209·0–322·0) in the placebo 
group. The most common grade 3–4 adverse events were fatigue (29 [18%] of 157 patients in the sorafenib group vs 
21 [13%] of 156 patients in the placebo group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea (16 [10%] vs four [3%]), 
gastrointestinal disorders (18 [11%] vs 12 [8%]), and hand–foot skin reaction (12 [8%] and none). At least one serious 
adverse event was reported in 65 (41%) of 157 patients in the sorafenib group and 50 (32%) of 156 in the placebo 
group, and 181 serious adverse events were reported in total, 95 (52%) in the sorafenib group and 86 (48%) in the 
placebo group. Three deaths occurred in each group that were attributed to DEB-TACE. Four deaths were attributed 
to study drug; three in the sorafenib group and one in the placebo group.
Interpretation The addition of sorafenib to DEB-TACE does not improve progression-free survival in European 
patients with hepatocellular carcinoma. Alternative systemic therapies need to be assessed in combination with TACE 
to improve patient outcomes.
Funding Bayer PLC and BTG PLC.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. 
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Introduction
Hepatocellular carcinoma is the sixth most common 
cancer and the second most common cause of death from 
cancer worldwide.1 Less than 30% of patients are eligible 
for potentially curative therapies such as trans plantation, 
resection, or ablation. For selected patients not suitable 
for such interventions but who have liver-confined 
disease, preserved liver function, and good performance 
status, transarterial chemoembolisation (TACE) is 
recommended according to international guidelines.2 
Articles
566 www.thelancet.com/gastrohep   Vol 2   August 2017
Hospital, Sutton, UK 
(D Cunningham MD); University 
of Liverpool, Liverpool, UK 
(P J Johnson MBBS, 
D H Palmer MBBS); and 
Clatterbridge Cancer Centre, 
Liverpool, UK (D H Palmer)
Correspondence to: 
Prof Tim Meyer, UCL Cancer 
Institute, University College 
London, London WC1E 6BT, UK 
t.meyer@ucl.ac.uk
The evidence for TACE comes from two small randomised 
controlled trials and a meta-analysis showing a significant 
survival benefit for TACE-treated patients compared with 
those receiving best supportive care.3–5 In clinical practice, 
the application of TACE varies widely with regard to 
embolic particle, chemotherapeutic used, frequency, and 
schedule of administration.6 Patient selection also varies 
in terms of tumour extent, vascular invasion, presence of 
extrahepatic disease, and performance status. Emerging 
evidence also calls into question the role of chemotherapy, 
suggesting that outcomes from bland embolisation (TAE) 
are equivalent to those of TACE;7,8 a Cochrane review9 also 
questioned the survival benefit attributable to TACE. The 
introduction of drug-eluting beads (DEB-TACE) has 
provided a method of embolising tumours with a more 
controlled local release of chemotherapy. Although this 
approach has not been shown to be superior to 
conventional TACE in terms of survival, less 
chemotherapy-associated toxicity occurs due to the lower 
systemic exposure to chemotherapy.10,11 Specifically, the 
extent of transaminitis and alopecia are reduced with 
DEB-TACE.10,12
For advanced disease, sorafenib is currently the 
standard of care based on the results of two large 
placebo-controlled, randomised trials showing a median 
survival benefit of 2–3 months.13,14 Sorafenib is a 
multikinase inhibitor targeting, among others, VEGFR, 
RAF, and PDGFR thereby exerting both anti-angiogenic 
and direct antitumour effects. The use of sorafenib as an 
adjuvant therapy after resection or ablation has been 
explored and found to be ineffective15 and a number of 
strategies have been explored in patients who receive 
TACE. TACE causes acute hypoxia leading to upregulation 
of VEGF, which might contribute to revascularisation. 
As such, the rationale is clear to combine TACE 
with sorafenib, to inhibit both revascularisation and 
tumour proliferation. We therefore did a randomised, 
placebo-controlled trial with the aim to assess the role of 
sorafenib combined with standard DEB-TACE.
Methods
Study design and participants
We did a phase 3 multicentre, randomised, double-blind, 
placebo-controlled study in 20 hospitals in the UK 
(appendix). Inclusion criteria included: histological 
or non-invasive diagnosis according to the American 
Association for the Study of Liver Diseases (AASLD) cri-
teria,16 aged 18 years or older, at least one unidimensional 
lesion measurable according to Response Evaluation 
Criteria In Solid Tumors version 1.1 (RECIST v1.1),17 
not being a candidate for surgical resection or liver 
transplant, Eastern Cooperative Oncology Group 
(ECOG) performance status of 1 or less, Child-Pugh A 
liver disease, haemo globin of 9 g/L or higher, neutrophil 
count of at least 1·5 × 10⁹ cells per L, platelet count of at 
least 60 × 10⁹ platelets per L, bilirubin of no more than 
50 µmol/L, aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) of 5 times upper limit of normal 
Research in context
Evidence before the study
We searched PubMed for articles published between Jan 1, 2000, 
and the start of the TACE 2 trial on Nov 1, 2010, using the search 
terms, “hepatocellular carcinoma” and “sorafenib”. This search 
yielded two randomised placebo-controlled trials assessing 
sorafenib as a single agent for the treatment of advanced 
hepatocellular cancer. These two trials confirmed a survival 
benefit of 2–3 months for patients with good performance 
status and Child-Pugh A liver disease. Additionally, we identified 
one phase 1 trial that showed the feasibility of combining 
sorafenib with transarterial chemoembolisation (TACE) in 
14 patients with hepatocellular carcinoma, but we identified no 
randomised trials including the combination of sorafenib and 
TACE. We therefore initiated the first randomised phase 3 trial of 
TACE combined with continuous sorafenib with the aim to 
determine the effect of addition of sorafenib on progression-free 
survival in patients treated with TACE. We did a subsequent 
search of PubMed for articles published between Nov 1, 2010, 
and April 12, 2017, using the search terms “sorafenib”, 
“hepatocellular carcinoma”, “TACE”, and “randomised”. This 
search identified three prospective trials. One trial was a phase 3 
trial comparing sorafenib with placebo in Japanese and Korean 
patients who had achieved at least 25% tumour necrosis after 
TACE, which showed no improvement in time to progression for 
individuals receiving sorafenib. By contrast, a small randomised 
trial of 80 patients infected with hepatitis C showed a significant 
improvement in time to progression for patients treated with 
TACE after sorafenib treatment compared with placebo. 
The only randomised trial to assess concurrent sorafenib and 
TACE was the SPACE trial: a global randomised phase 2 trial, 
which showed no improvement in time to progression for 
sorafenib and TACE versus TACE alone. Follow-up in the SPACE 
trial was too short to provide a meaningful comparison of 
overall survival.
Added value of this study
To our knowledge, the TACE 2 trial is the first phase 3 trial to 
compare continuous, concurrent sorafenib combined with 
TACE versus the combination of placebo and TACE. We found 
no evidence of an improvement in the primary endpoint, 
progression-free survival, or the secondary endpoint, overall 
survival.
Implications of all available evidence
Together with the existing evidence, we believe that this trial 
provides definitive evidence that the combination of sorafenib 
and TACE, while feasible, is not effective, and alternative 
strategies to improve outcomes for intermediate stage 
hepatocellular carcinoma should be explored.
See Online for appendix
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or less, alkaline phosphatase (ALP) of less than 4 times 
upper limit of normal, creatinine of 1·5 times upper 
limit of normal or less, international normalised ratio 
(INR) of 1·5 times upper limit of normal or less, and left 
ventricular ejection fraction of at least 45%. Exclusion 
criteria included: extrahepatic metastasis, previous 
embolisation, systemic therapy or radiotherapy for 
hepatocellular carcinoma, any contraindication to 
hepatic embolisation, previous investigational therapy, 
major surgery or history of bleeding within 4 weeks of 
trial entry, hepatic encephalopathy, occlusion of the 
hepatic artery or main portal vein, myocardial infarction 
within 6 months or prolonged QT/QTc of more than 
450 ms. The protocol was approved by the central ethical 
review board (IRAS Ref 09/H1102/114) and all patients 
provided written informed consent.
Randomisation and masking
The Cancer Research UK Clinical Trial Unit (CRCTU; 
Birmingham, UK) was responsible for managing the 
randomisation, drug allocation, and drug discontinuation 
processes using an online trial management portal. 
Randomisation was done by randomisation officers 
based at CRCTU. Sharp Clinical Services (Crickhowell, 
UK) managed drug labelling and drug dispensing. 
Patients were randomly assigned, on a 1:1 basis and in a 
masked fashion, to the sorafenib group or placebo group 
based on a minimisation randomisation algorithm. 
Randomisation was stratified by randomising centre and 
serum α-fetoprotein (AFP) concentration (<400 ng/mL 
and ≥400 ng/mL). At randomisation, staff at the CRCTU 
verified patient details and eligibility criteria before 
informing the site of trial number and treatment 
allocation. Allocation concealment was achieved by the 
use of tablets identical in appearance and in numbered 
bottles. Bottles contained 70 days’ supply of sorafenib or 
matching placebo. The CRCTU randomisation system 
allocated patients to each treatment group and directly 
informed the pharmacy at each site of the numbered 
bottle to distribute to which patients. To maintain 
masking throughout the trial, all subsequent issue of 
study medication was managed by CRCTU through the 
allocation and provision of bottle numbers at each 
follow-up visit. Only the trial coordinator was unmasked 
to treatment allocation before patient progression during 
the study. Patients were unmasked only in the event of a 
suspected unexpected serious adverse reaction. The trial 
co ordinator only did the unmasking after the clinical 
coordinator had confirmed expectedness for the serious 
adverse reaction. The result was kept confidential. On 
disease progression, patients were unmasked to allow 
for further clinical decision making and for the provision 
of open-label sorafenib. This process was managed 
through the online trial management portal by the trial 
coordinator at CRCTU. The trial statistician had access 
to the unmasked information in accordance with 
CRCTU standard operating procedures. At the end of 
the study, an unmasked patient randomisation report 
was run from the system by the statistician and provided 
to the trial coordinator to match the patient by trial 
number and date of birth.
Procedures
Oral sorafenib at a dose of 400 mg twice-daily or 
matching placebo was commenced within 24 h of 
randomisation and continued until disease progression 
according to RECIST v1.1. Two dose reductions, level –1 
(400 mg once-daily) and level –2 (400 mg alternated 
days), were defined in the protocol, and drug was 
discontinued in the event of disease progression, 
protocol-defined unacceptable toxicity, a dose inter-
ruption of more than 30 days, patient choice, or the 
recommendation of the investigator. DEB-TACE was 
given 2–5 weeks post-randomisation using drug-eluting 
Figure 1: Trial profile
399 patients screened and consented
313 patients randomised (recruitment ceased
 early in September, 2015, based on futility)
157 assigned sorafenib + TACE
157 received sorafenib, TACE, or both
68 discontinued treatment early 
 27 toxicity 
 19 patient choice 
 3 other adverse event 
 2 administered  other
 therapy 
 1 second malignancy 
 15 other 
 1 not provided 
 5 declined
81 ineligible 
 6 missing data 
 8 cardiac issues 
53 screening failure 
 3 other treatment
11 extrahepatic disease
86 not randomised, failed screening
16 full withdrawal from study
 9 patient choice 
 6 other 
 1 unknown 
Records contributing to survival
analyses
157 intention to treat
113 per protocol
156 assigned placebo + TACE
156 received placebo, TACE, or both
40 discontinued treatment early 
 9 toxicity 
 3 patient choice 
 7 other adverse event 
 3 administered other
 therapy 
 1 second malignancy 
 17 other 
 0 not provided 
15 full withdrawal from study
 3 patient choice 
 11 other 
 1 unknown 
Records contributing to survival
analyses
156 intention to treat
134 per protocol
For the online protocol see 
http://www.birmingham.ac.uk/
Documents/college-mds/trials/
crctu/tace2/TACE-2-Protocol-
v8-0-28-Jun-2016-Clean-CI-
signed.pdf
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beads (DC Bead; BTG PLC, London, UK) loaded with 
doxorubicin 150 mg according to the manufacturer’s 
instructions. Administration was via the hepatic artery 
accessed via the femoral artery, and a superselective 
approach was recommended. The protocol advised first 
injecting the smaller DC Bead (100–300 µm) followed by 
the larger DC Beads (300–500 µm) to achieve the 
angiographic endpoint defined as sluggish flow in the 
main feeding vessels with stasis in the intralesional 
and perilesional branches. The maximum delivery 
dose was two vials of DC Beads loaded with 75 mg 
doxorubicin per vial. All baseline screening tests were 
required within 28 days of randomisation. Baseline 
imaging and follow-up imaging was done by CT of the 
chest and dual phase abdominal CT or contrast enhanced 
abdominal MRI. The first follow-up imaging was done at 
week 10 post-randomisation and further DEB-TACE 
was given as required according to the presence of 
persistent tumour enhancement. Further follow-up 
imaging was done at week 22 and every 3 months there-
after. Laboratory evaluation, including haematology, 
coagulation, bio chemistry, and AFP tests, was done 
during screening and on day 1, 72 h before DEB-TACE, 
8 days post-DEB-TACE, week 10, and every 6 weeks 
thereafter. Left ventricular ejection fraction was 
estimated by echocardiography or multigated acquisition 
scan during screening, and electro cardiograms were 
performed during screening, within 72 h of DEB-TACE, 
day 7 post-TACE, week 10, and every 6 weeks thereafter. 
Toxicity was graded according to the National Cancer 
Institute (NCI) Common Terminology Criteria for 
Adverse Events version 4.0 (CTCAE v4.0) and was 
recorded from the start of study treatment up to 30 days 
after last administration of study treatment or until end 
of study. Quality of life (QOL) was assessed using the 
European Organisation for Research and Treatment of 
Cancer (EORTC) QOL questionnaire (QLQ-C30) 
version 3, EORTC QLQ-HCC18, and the EuroQoL 
(EQ-5D) questionnaire, which were requested at 
baseline, pre-TACE, week 10, and every 6 weeks 
thereafter until progression. On progression, patients 
were unmasked and entered the post-study treatment 
period. To avoid delays in unmasking and initiating 
appropriate treat ment on progression, an amendment 
was implemented during the trial to allow unmasking 
on local review rather than central review. Patients in the 
placebo group were offered sorafenib at the discretion of 
the treating clinician and patients in the sorafenib group 
could continue if there was deemed to be patient benefit. 
No standard therapy was recommended for patients 
progressing on sorafenib who discontinued sorafenib.
Outcomes
The primary endpoint was progression-free survival 
defined as the interval between randomisation and 
progression according to RECIST v1.117 or death due to 
any cause. Patients who did not progress or die were 
TACE with 
sorafenib 
(n=157)
TACE with 
placebo 
(n=156)
Sex
Male 139 (89%) 138 (88%)
Female 18 (11%) 18 (12%)
Age (years) 65 (57–71) 68 (63–74)
AFP (KU/L) 23 (5–241) 25 (5–280)
Creatinine (µmol/L) 75 (64–89) 75 (65–92)
Bilirubin (µmol/L) 14 (9–21) 13 (10–20)
ECOG PS
0 98 (62%) 97 (62%)
1 58 (37%) 58 (37%)
Not known 1 (1%) 1 (1%)
Disease focality
1 59 (38%) 40 (26%)
2 33 (21%) 41 (26%)
3 16 (10%) 17 (11%)
>3 42 (27%) 49 (31%)
Not known 7 (4%) 9 (6%)
Unilobar 94 (60%) 76 (49%)
Patient has cirrhosis 129 (82%) 122 (78%)
Cause of cirrhosis
Alcohol 44 (34%) 40 (33%)
Hepatitis C 15 (12%) 9 (7%)
Hepatitis C and alcohol 10 (8%) 12 (10%)
Hepatitis B 7 (5%) 7 (6%)
Hepatitis B, hepatitis C 3 (2%) 3 (2%)
Hepatitis B, hepatitis C, and alcohol 3 (2%) 2 (2%)
Hepatitis B and alcohol 2 (2%) 2 (2%)
Other 45 (35%) 47 (39%)
Diagnosis method
Histology 35 (22%) 47 (30%)
Radiology 122 (78%) 106 (68%)
Not known 0 3 (2%)
Dominant tumour diameter (cm) 6 (4–8) 5 (4–8)
Previous liver resection or ablative 
therapy
11 (7%) 20 (13%)
Child-Pugh score
5 106 (68%) 114 (73%)
6 39 (25%) 34 (22%)
7 4 (3%) 2 (1%)
8 1 (1%) 1 (1%)
Not known 7 (4%) 5 (3%)
HAP score
HAP A 44 (28%) 43 (28%)
HAP B 52 (33%) 61 (39%)
HAP C 41 (26%) 34 (22%)
HAP D 14 (9%) 10 (6%)
Not known 6 (4%) 8 (5%)
Data are n (%) for categories, and median (IQR) for continuous data. 
TACE=transarterial chemoembolisation. AFP=α-fetoprotein. ECOG PS=Eastern 
Cooperative Oncology Group performance status. HAP=hepatoma 
arterial-embolisation prognostic.
Table 1: Baseline characteristics
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censored at the date last known to be event-free. The 
primary endpoint was determined by local review and 
additional central review was provided by IXICO plc 
(London, UK). Secondary endpoints included: overall 
survival measured from date of randomisation to death; 
time to progression, measured from date of random-
isation to date of progression; response and disease 
control according to RECIST v1.1 guidelines; QOL, 
scored according to the EORTC manuals; and number 
of TACE procedures given within 12 months of 
randomisation. Toxicity was assessed in all patients 
according to NCI CTCAE v4.0 from the start of study 
treatment until 30 days after last administration of study 
treatment or until the end of the study. All serious 
adverse events were assessed with reference to the 
summary of product characteristics (SmPC) for sorafenib 
and clinically assessed in a masked fashion. Unmasking 
only occurred at the point of requirement for suspected 
unexpected serious adverse event (SUSAR) reporting. 
Response according to mRECIST18 was collected 
prospectively and an exploratory comparison with 
RECIST v1.1 was planned on completion of the study.
Statistical analysis
The null hypothesis was that the survival distributions 
were equal, and the alternative, that the survival 
distributions differed. We calculated that 412 patients 
were required to detect an improvement in median 
progression-free survival from 8·9 months to 
12·4 months, equating to a hazard ratio (HR) for 
DEB-TACE and sorafenib of 0·72, with a two-sided α of 
0·05, and with 85% power. The design incorporated 
a formal interim analysis for futility following the 
method of Freidlin and colleagues,19 after 147 (43%) of 
progression-free survival events, at which a HR of 1 or 
more would be indicative of futility. Overall error rates 
were not adjusted for the interim analyses. Sample size 
was estimated using PS software (version 3.0.2). Primary 
efficacy analyses were done in the intention-to-treat 
population, which included all random ised patients. 
Further analyses assessed efficacy in the per-protocol 
population, defined as all patients receiving at least one 
DEB-TACE and 6 weeks of sorafenib or placebo, and 
excluding ineligible patients. Safety was assessed in the 
intention-to-treat population. We analysed the primary 
outcome of progression-free survival and secondary 
outcome measures, overall survival and time to 
progression, through multilevel flexible parametric 
survival models with adjustment for stratification 
factors, with randomising centre entered as a random 
component. We estimated HR with 95% CI, and the 
placebo group was the reference group in all cases. We 
did sensitivity analyses with adjustment for prognostic 
factors identified in univariable analyses. We tested the 
proportional hazards assumption when applicable. 
Efficacy was also assessed in prognostic subgroups, 
including stratification factors, with tests of heterogeneity. 
QOL was explored graphically by fitting smoothed trends 
to the observed data, and analysed QOL data through 
mixed-effects linear regression models with the random 
component specified at the patient level. Exploratory 
interactions between treatment group and time from 
randomisation allowed trends to differ by treatment 
group. We assumed patients had the worst possible 
symptomatic score, or lowest level of functioning at 
death. We assessed model fit for survival and QOL 
measures through Akaike-information criterion and 
Bayesian-information criterion. Modelling of the EQ5D 
utility score with overall survival on the basis of the 
integrated quality survival product methods of 
Billingham and colleagues20 will be reported in a 
subsequent publication. We report safety data 
descriptively, with adverse events summarised as 
worst-grade experienced at the patient level for each 
CTC category, and with frequency of serious adverse 
events reported by treatment group and their relative 
expectedness to sorafenib. Deaths deemed associated 
with treatment must have occurred within 30 days of last 
treatment. Data were analysed with Stata version 14. 
The trial was registered on the European Clinical 
Trials Database (EudraCT Number: 2008-005073-36), 
the ISRCTN registry (ISRCTN93375053), and 
ClinicalTrials.gov (NCT01324076).
Role of the funding source
The funders of the study (Bayer PLC and BTG PLC) had 
no role in the study design, data collection, analysis, 
interpretation, or writing of the report. Bayer PLC 
provided sorafenib and matching placebo and BTG 
provided DC Beads. The study was endorsed by Cancer 
Research UK and adopted into the NIHR trial portfolio. 
The study was sponsored by UCL and the chief investigator 
TACE with sorafenib 
(n=157)
TACE with placebo 
(n=156)
Number of TACE procedures
0 11 (7%) 7 (5%)
1 65 (41%) 44 (28%)
2 40 (26%) 55 (35%)
3 21 (13%) 22 (14%)
4 10 (6%) 14 (9%)
>5 4 (3%) 10 (6%)
Not known 6 (4%) 4 (3%)
TACE procedures in first 
12 months
268 326
Duration of treatment 
(days)
120·0 (43·0–266·0) 162·0 (70·0–323·5)
Patient duration-weighted 
median dose (mg)
660·0 (389·2–800·0) 800·0 (758·2–800·0)
Data are n (%) for categories, and median (IQR) for continuous data. 
DEB-TACE=drug-eluting beads transarterial chemoembolisation. DEB=drug-eluting 
beads. TACE=transarterial chemoembolisation.
Table 2: Study drug and DEB-TACE administration and efficacy outcomes
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(TM) is employed by UCL. The study was designed by TM 
and members of the trial management group including 
DHP, PJJ, JNP, AW, NH, DS, RF, and CS. The trial was 
monitored by an independent data monitoring committee 
(IDMC) who had full access to the data and reported to the 
trial steering committee (TSC). Both the IDMC and TSC 
approved termination of recruitment. Data collection and 
analysis was done by the CRCTU. TM, RF, and CS had 
access to the raw data and the corresponding author (TM) 
had full access to all of the data and the final responsibility 
to submit for publication.
Results
Between Nov 4, 2010, and Dec 7, 2015, 313 patients were 
randomised; 157 to sorafenib and 156 to placebo (figure 1). 
Patient characteristics were similar between groups 
(table 1). Of the 313 patients randomly assigned to 
treatment, their median age was 67 years (IQR 60–73), 
277 (89%) percent were men, 195 (62%) had an ECOG 
performance score of 0, and 251 (80%) had cirrhosis 
(table 1). All patients were Child-Pugh A at screening; at 
randomisation, Child-Pugh score was 5 in 220 (70%) of 
331 patients and was 6 in 73 patients (23%); eight (3%) of 
313 patients had become Child-Pugh B (table 1). The 
most common known single cause for liver disease was 
alcohol (table 1). The median daily dose of sorafenib was 
660 mg (IQR 389·2–800·0) compared with 800 mg 
(758·2–800·0) for placebo and the median duration of 
treatment was 120·0 days (IQR 43·0–266·0) versus 
162·0 days (70·0–323·5; table 2).
274 DEB-TACE procedures were given within the 
sorafenib group and 340 procedures were given within 
the placebo group; 268 (98%) of 274 procedures, and 
326 (96%) of 340 procedures were done within the first 
12 months from randomisation. The most commonly 
used bead size was 100–300 µm, which was used in 
205 (75%) of 274 embolisation procedures in the 
sorafenib group and 240 (71%) of 340 procedures in the 
placebo groups. 100% of the loaded beads (two vials) 
were administered in 144 (53%) of the 274 embolisation 
procedures in the sorafenib group and 203 (60%) of the 
340 procedures in the placebo group. The angiographic 
endpoint was reached in 232 (85%) procedures in the 
sorafenib group and 275 (81%) in the placebo group. 
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Figure 2: Kaplan-Meier plots for survival outcomes
(A) Progression free survival; (B) overall survival; (C) time to progression; and (D) overall survival by HAP score. HAP=hepatoma arterial-embolisation prognostic. HR=hazard ratio.
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At least one DEB-TACE was delivered to 285 (91%) of all 
patients; 140 (89%) of 157 in the sorafenib group and 
145 (93%) of 156 in the placebo group. 56 (36%) patients 
in the placebo group received post-progression sorafenib.
The formal interim futility analysis of progression-free 
analysis was done in July, 2015, and indicated an HR of 
1·03 (95% CI 0·75–1·42, p=0·85), which led to early trial 
closure. We then analysed the final data, which included 
additional data accrued during trial closure period, by 
which point 31 patients had fully withdrawn from the 
study. The median follow-up was 620·0 days (95% CI 
572–784), and 246 progression-free survival events 
and 164 overall survival events had been observed. There 
was no evidence of a difference in progression-free 
survival, the primary outcome, between the sorafenib 
group and the placebo group. Median progression-free 
survival was 238·0 days (95% CI 221·0–281·0) in the 
sorafenib group versus 235·0 days (209·0–322·0) in the 
placebo group (HR 0·99 [95% CI 0·77–1·27], p=0·94; 
figure 2). A high proportion of scans (22%) were not 
reported by central review, making robust interpretation 
of outcomes by central review unreliable.
Similarly, there was no evidence of a difference in 
overall survival between groups: median overall survival 
was 631·0 days (95% CI 437·0–879·0) in the sorafenib 
group versus 598·0 days (500·0–697·0) in the placebo 
group (HR 0·91 [95% CI 0·67–1·24], p=0·57; figure 2). 
There was also no evidence of a difference time to 
progression also between the sorafenib group and the 
placebo group, with an HR of 0·88 (95% CI 0·67–1·17, 
p=0·38; figure 2); median time to progression was 
326·0 days (95% CI 240·0–410·0) in the sorafenib group 
versus 320·0 (234·0–400·0) in the placebo group. 
Sensitivity analyses involving adjustment for prognostic 
factors identified through univariable analyses confirmed 
no evidence of a difference for all survival measures: 
the HR for progression-free survival was 1·01 
(95% CI 0·78–1·30; p=0·94); the HR for overall survival 
was 0·99 (95% CI 0·73–1·35; p=0·96); and the HR for 
time to progression was 0·87 (95% CI 0·66–1·16; 
p=0·35). Furthermore, analyses in the per-protocol 
population, which comprised 113 patients in the sorafenib 
group and 134 in the placebo group, also revealed no 
evidence of a difference for all survival measures (data not 
shown). The proportional hazards assumption was 
upheld throughout. The hepatoma arterial-embolisation 
prognostic (HAP) score was also confirmed as a robust 
method of prognostic stratification resulting in a median 
overall survival of 946·0 days (95% CI 641·0–1316·0) for 
HAP A, 631·0 days (510·0–816·0) for HAP B, 463·0 days 
(259·0–573·0) for HAP C, and 169·0 (86·0–420·0) for 
HAP D (figure 2); but in the subgroup analysis, there was 
no indication of a treatment effect in any HAP category 
(figure 3). Subgroup analyses according to AFP, tumour 
size, ECOG performance status, hepatitis C aetiology, and 
focality did not suggest a survival benefit, indicating that 
sorafenib did not confer benefit for progression-free 
survival or overall survival, even in the high-risk group—
defined by a higher HAP score, high AFP or greater 
tumour burden (figure 3).
According to RECIST v1.1, 56 (36%) of 157 patients in 
the sorafenib group and 49 (31%) of 156 in the placebo 
group had an overall response (ie, complete response or 
partial response; table 3); 117 (75%) patients in the 
sorafenib group and 121 (78%) in the placebo group 
achieved disease control (ie, complete response, partial 
Figure 3: Subgroup analyses of (A) progression-free survival and (B) overall survival for known prognostic 
factors
HAP=hepatoma arterial-embolisation prognostic. ECOG PS=Eastern Cooperative Oncology Group performance 
status. AFP=α-fetoprotein levels. *Not pre-planned.
 Hazard ratio (95% CI)  Hazard ratio (95% CI)
B
Favours sorafenib Favours placebo
0·25 0·5 1 1·5 2·5
Favours sorafenib Favours placebo
0·25 0·5 1 1·5 2·5
A
Overall
≤7
>7
Dominant tumour size (cm)*
≤3
>3
Disease focality (number of nodules)*
No
Yes
Hepatitus C-related*
≤400
>400
AFP (ng/ml)
0
1
ECOG PS
HAP A
HAP B
HAP C
HAP D
HAP score
TACE with sorafenib (n=157) TACE with placebo (n=156)
RECIST v1.1 mRECIST RECIST v1.1 mRECIST
Complete response 4 (3%) 45 (29%) 5 (3%) 36 (23%)
Partial response 52 (33%) 39 (25%) 44 (28%) 45 (29%)
Stable disease 61 (39%) 33 (21%) 72 (46%) 39 (25%)
Disease progression 15 (10%) 13 (8%) 17 (11%) 15 (10%)
Overall response* 56 (36%) 84 (54%) 49 (31%) 81 (52%)
Disease control† 117 (75%) 117 (75%) 121 (78%) 120 (77%)
Not evaluated or available 25 (16%) 27 (17%) 18 (12%) 21 (14%)
Data are n (%) for categories, and median (IQR) for continuous data. RECIST=Response Evaluation Criteria In Solid 
Tumors. mRECIST=modified RECIST. TACE=transarterial chemoembolisation. *Complete or partial response. 
†Complete response, partial response, or stable disease.
Table 3: Disease response assessed locally using RECIST v1.1 and modified RECIST criteria
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response, or stable disease; table 3). Response was also 
assessed locally using modified RECIST (mRECIST), as 
shown in table 3.
1764 QOL questionnaire forms were returned by 
289 (92%) of 313 patients, with 140 (89%) of 157 patients in 
the sorafenib group, and 149 (96%) of 156 in the placebo 
group returning at least one form. According to multilevel 
regression of QLQ-C30 scores over 360 days, both the 
mean social and role functioning scales were found to be 
up to 6% lower (p=0·045 and p=0·050) for patients in the 
sorafenib group (figure 4). Of the symptom scales, mean 
diarrhoea score was up to 13% higher on average in the 
sorafenib group (p=0·0095) and mean appetite loss score 
was up to 10% higher (p=0·0018). According to HCC18, 
mean nutritional problem scores were up to 7% worse 
in the sorafenib group (p=0·0084; data not shown). 
No evidence of non-zero interactions was observed. No 
significant differences were observed in other QOL scales.
The addition of sorafenib did not seem to increase 
toxicity associated with DEB-TACE, as evidenced by 
similar incidence of abdominal pain and nausea (table 4). 
The major differences between the two groups were 
consistent with well-known toxicities associated with 
sorafenib, namely stomatitis, diarrhoea, hand–foot skin 
reaction, rash, and bleeding, which were all more common 
in the sorafenib group. The most common grade 3–4 
adverse events were fatigue (29 [18%] of 157 patients in the 
sorafenib group vs 21 [13%] of 156 patients in the placebo 
group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea 
(16 [10%] vs four [3%]), gastrointestinal disorders (18 [11%] 
vs 12 [8%]) and hand–foot skin reaction (12 [8%] and none). 
At least one serious adverse event was reported in 65 (41%) 
of 157 patients in the sorafenib group and 50 (32%) of 
156 patients in the placebo group. 181 serious adverse 
events were reported in total: 95 (52%) in the sorafenib 
group and 86 (48%) in the placebo group. Deaths were 
classified as treatment-related if the death was reported as 
possibly, probably, or definitely related, by the local 
primary investigator. There were three deaths in each 
group that were attributed to DEB-TACE, occurring 
between 36·0 days and 249·0 days after randomisation. 
Four deaths were attributed to study drug, one of which, 
based on masked review, was in the placebo group and 
was caused by massive variceal haemorrhage. Of the three 
treatment-related deaths in the sorafenib group, one was 
after acute liver failure 14·0 days after randomisation, the 
second due to infection 134·0 days after randomisation, 
and the third due to hepatorenal failure 250·0 days after 
randomisation.
Figure 4: Restricted cubic splines fit to quality-of-life scales
Quality of life was measured through EORTC QLQ-C30 and QLQ-HCC18. 
All scales and single-item measures range in score from 0 to 100. A high scale 
score represents a higher response level. Thus a high score for a functional scale 
represents a high or healthy level of functioning, but a high score for a symptom 
scale represents a high level of symptomatology or problems. Functioning scales 
were (A) role, and (B) social. Symptom scales were (C) appetite loss, 
(D) diarrhoea, and (E) nutrition. 
E
N
ut
rit
io
n 
sc
or
e
0 90 180 360
Time (days)
D
Di
ar
rh
oe
a 
sc
or
e
C
Ap
pe
tit
e 
lo
ss
 sc
or
e
B
So
cia
l f
un
ct
io
ni
ng
  s
co
re
TACE + sorafenib
TACE + placebo
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
A
Ro
le
 fu
nc
tio
ni
ng
 sc
or
e
60
70
80
90
100
Articles
www.thelancet.com/gastrohep   Vol 2   August 2017 573
Discussion
The combination of sorafenib and TACE has been assessed 
in a number of single arm phase 1 and 2 trials in which 
both sequential and concurrent administration has been 
shown to be feasible and safe.21–24 Sequential therapy was 
found to be ineffective in a large randomised controlled 
trial25 done in Japan and South Korea in which patients 
with at least 25% necrosis after TACE were randomised to 
sorafenib or placebo 1–3 months post-TACE. There was no 
significant difference in time to progression but the daily 
dose of sorafenib administered was very low (median 
387 mg). Additionally, the anti-angiogenic agent brivanib 
has also been assessed as an adjuvant therapy after TACE 
a large phase 3 trial,26 which was terminated early after 
randomisation of 502 patients when intention-to-treat 
analysis showed no improvement in overall survival. 
However, there is a strong rationale for concurrent rather 
than sequential therapy in view of the potential of 
sorafenib to suppress the angiogenic effect of VEGF 
released by the acute hypoxia induced by TACE. The 
feasibility of this approach was first shown in an initial 
phase 1 trial21 that assessed escalating doses of sorafenib 
combined with doxorubicin-based conventional TACE, 
and confirmed that sorafenib could be safely given at full 
dose continuously from 7 days before TACE. In support of 
the rationale for the combination, the plasma concentration 
of VEGF was found to be reduced after combined therapy 
by contrast with increases previously reported in response 
to TACE alone. A subsequent phase 2 trial22 confirmed the 
safety of this approach in combination with DEB-TACE 
and also reported disease control in 95% of patients. 
A global placebo-controlled randomised phase 2 trial 
(SPACE)27 has been reported for which time to progression 
was the primary endpoint. Patients were randomly 
allocated to sorafenib 400 mg twice-daily or matched 
placebo starting 2–7 days before the first TACE performed 
using DEB-TACE. Additional DEB-TACE was given 
according to fixed schedule at cycle 3, 7, and 13, and every 
six cycles thereafter, where each cycle was 4 weeks long. 
The primary endpoint was determined by central 
radiological review according to mRECIST criteria. The 
SPACE trial did not show a clinically meaningful 
improvement in time to progression with the addition of 
sorafenib, but the study had significant methodological 
flaws that were acknowledged by the authors and that 
could have compromised the outcome. First, almost 
30% patients were not evaluable for the primary endpoint 
since a primary target lesion could not be defined by the 
central reviewers. Second, the strict criteria for retreatment 
resulted in a high rate of non-compliance with 30% 
receiving further TACE in breach of the protocol. Third, 
the treatments delivered in different geographical 
locations differed significantly, which might have 
contributed to different outcomes. Finally, although 
overall survival was a predefined secondary endpoint, the 
trial was reported before median overall survival had 
been reached.
To our knowledge, TACE 2 is the first randomised, 
placebo-controlled, phase 3 trial to explore the 
concurrent administration of sorafenib and DEB-TACE. 
We aimed to compare combination treatment with 
sorafenib and DEB-TACE versus treatment with 
DEB-TACE alone (controlled with placebo). Because 
sorafenib was standard of care for patients progressing 
after TACE, and to ensure patients were not 
disadvantaged by participation, all patients were 
unmasked on progression and allowed to crossover to 
sorafenib if they were in the placebo group. No post-
progression therapy was recommended for those on 
sorafenib because no effective second-line therapies 
were available during the recruitment period. We 
reasoned that the high rate of crossover to sorafenib 
might obscure any benefit of the combination if 
overall survival was chosen as the primary endpoint. 
Furthermore, the choice of time to progression as an 
endpoint might obscure toxicity leading to death in the 
combination arm. Hence, we felt that progression-free 
survival was the most appropriate primary endpoint, 
but both overall survival and time to progression were 
included as secondary endpoints. By contrast with the 
SPACE trial, the endpoint for TACE 2 was determined 
by local review. Study drug was commenced 2–5 weeks 
before DEB-TACE, allowing a suitable period to 
establish a tolerable dose, and subsequent DEB-TACE 
TACE with sorafenib (n=157) TACE with placebo (n=156)
Grade 1/2 Grade 3 Grade 4 Grade 5 Grade 1/2 Grade 3 Grade 4 Grade 5
Fatigue 98 (62%) 28 (18%) 1 (1%) 0 101 (65%) 20 (13%) 1 (1%) 0
Abdominal pain 73 (47%) 20 (13%) 0 0 77 (49%) 12 (8%) 0 0
Diarrhoea 71 (45%) 15 (10%) 1 (1%) 0 45 (29%) 4 (3%) 0 0
Nausea 70 (45%) 2 (1%) 0 0 66 (42%) 1 (1%) 0 0
Rash 57 (36%) 3 (2%) 0 0 32 (21%) 0 0 0
Hand foot skin 
reaction
53 (34%) 12 (8%) 0 0 13 (8%) 0 0 0
Stomatisis 36 (23%) 5 (3%) 0 0 17 (11%) 1 (1%) 0 0
Bleed 21 (13%) 7 (5%) 2 (1%) 0 14 (9%) 1 (1%) 1 (1%) 0
Anorexia 50 (32%) 3 (2%) 0 0 50 (32%) 2 (1%) 0 0
Constipation 23 (15%) 0 0 0 46 (30%) 0 0 0
Gastrointestinal 
disorders
7 (5%) 16 (10%) 2 (1%) 0 6 (4%) 10 (6%) 2 (1%) 1 (1%)
Pain 22 (14%) 0 0 0 18 (12%) 0 0 0
Vomiting 21 (13%) 2 (1%) 0 0 16 (10%) 0 1 (1%) 0
Dry skin 21 (13%) 0 0 0 15 (10%) 1 (1%) 0 0
Alopecia 21 (13%) 0 1 (1%) 0 14 (9%) 0 0 0
Pruritus 11 (7%) 0 0 0 21 (14%) 2 (1%) 0 0
Weight loss 19 (12%) 0 0 0 13 (8%) 0 0 0
General disorders 
and 
administration 
site conditions
7 (5%) 8 (5%) 0 1 (1%) 8 (5%) 3 (2%) 0 2 (1%)
CTC=Common Terminology Criteria. TACE=transarterial chemoembolisation.
Table 4: CTC adverse event categories (occurring in 10% or more of patients)
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was according to clinical demand rather than a fixed 
schedule. Finally, although the SPACE trial was a global 
study, TACE 2 was done exclusively in the UK and 
recruited over a longer time period, thereby providing 
sufficient follow-up to report mature survival data. 
Despite these important differences, TACE 2 and 
SPACE were similar in the treatment delivered; the 
median dose of sorafenib was approximately 25% lower 
than that of placebo and was given for a shorter period 
in both studies. In TACE 2, administration of sorafenib 
did not seem to compromise the subsequent delivery or 
efficacy of TACE because the number of patients who 
received at least one DEB-TACE was equivalent between 
arms, as was the volume of DC Beads administered and 
the proportion of patients achieving the angiographic 
endpoint. However, nearly half of the patients in the 
sorafenib group received less than two DEB-TACE 
treatments compared with just over a third in the 
placebo group, and fewer TACE procedures occurred in 
the first 12 months in the sorafenib group than in the 
placebo group. Possible explanations for fewer TACE 
procedures being given in the sorafenib group include 
toxicity from sorafenib precluding TACE, or that the 
efficacy of sorafenib obviated the need for TACE. The 
fact that the clinical outcomes of the two groups were 
equivalent favour the efficacy explanation, although an 
effect of additional toxicity cannot be excluded. Indeed, 
the analyses of QOL revealed some detriment to 
functioning, and increased symptoms for patients 
receiving sorafenib. In each of the scales that were 
found to differ, graphical analyses suggest that 
increased diarrhoea continued throughout the analysed 
period, while for appetite loss and nutritional symptoms, 
and the role and social functioning scales, the 
differences were most pronounced in the period up to 
180 days post-randomisation. Because gastrointestinal 
and dietary complications are recognised side-effects of 
sorafenib and TACE, these findings are plausible, 
especially in the period when both TACE and sorafenib 
are received. Equally, role and social functioning could 
deteriorate on receipt of combined therapy. Other than 
for diarrhoea, the difference in these scales for average 
QOL was reduced beyond 180 days. However, at 
approximately 270 days there was a suggestion of 
renewed detriment. We note that this coincides 
approximately with the median duration of progression-
free survival.
Despite the design and delivery of the TACE 2 trial, 
comparison of the two groups did not provide evidence 
of a significant or meaningful difference between groups 
in progression-free survival, overall survival, or time to 
progression. Similarly, although not formally compared, 
disease control and best response did not seem to differ 
between treatments. We believe that these results, taken 
together with those from the SPACE trial, provide 
definitive evidence that combined therapy does not 
improve outcome compared with DEB-TACE alone. 
In light of this, an unmet need remains to 
improve outcomes for intermediate stage hepatocellular 
carcinoma and alternative systemic therapies combined 
with TACE need to be explored. To this end, TACE 2 has 
provided useful data to inform the design of future 
TACE-based trials. First, we have prospectively evaluated 
both RECIST v1.1 and mRECIST as radiological response 
criteria and have confirmed our previously published 
retrospective finding, that progression is equivalent 
regardless of which criteria are applied.28 Hence, for the 
assessment of both time to progression and progression-
free survival, we believe either RECIST v1.1 or mRECIST 
can be used. Although the proportion of patients who 
had an overall response or achieved disease control was 
similar by each method, there were discrepancies 
between RECIST v1.1 and mRECIST, the most significant 
of which was the major difference between the 
two criteria in the definition of complete response 
(which occurred in 3% of patients by RECIST v1.1 
compared with 26% by mRECIST).
Within the context of a prospective trial, we have also 
validated the HAP score which was designed to provide 
prognostic information for patients undergoing TACE.29 
The data points for the HAP score were collected 
prospectively as part of the TACE 2 data-set and, as in 
our original study, the HAP score was able to define 
four distinct prognostic groups with respect to overall 
survival. The risk of death was significantly higher for 
individuals with a HAP score of D (HR 5·8, 95% CI 
3·2–10·6, p<0·0001) compared with HAP A and median 
survival was only 169·0 days for this group. We therefore 
propose that the HAP score could be used as a 
stratification factor for TACE trials in future.
In summary, the TACE 2 trial contributes compelling 
evidence that the concurrent administration of sorafenib 
with DEB-TACE does not improve outcomes compared 
with DEB-TACE alone, and also provides valuable lessons 
to inform future trial development.
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